Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, GLP-1RA, GLP-1RA + Basal, Other, SGLT2i, Topics Feb 25 | 2025Lilly Stockpiles Orfoglipron; February CHMP Agenda ObservedPurchase Blast
$599
Posted in: Other, Topics Feb 25 | 2025Coming Soon: FENIX Obesity Spotlight SeriesPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Feb 21 | 2025Sema Shortage Resolved; Pfizer/Viking M&A Rumor; Insulet Q4 ’24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Feb 20 | 2025Zealand FY Q4 ‘24 Earnings; Steve Pacelli Leaves DexcomPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Topics Feb 19 | 2025New Tandem AID Algorithm TrialPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Feb 18 | 2025Medtronic CY Q4 ’24 (FY Q3 ‘25) Earnings; FDA Approves Biosimilar Novolog; Allurion Balloon + GLP-1RA; Ph2 Oral VK2735 Trial ObservedPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other, Topics Feb 14 | 2025Dexcom Q4 '24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 13 | 2025Zepbound SDV Label Update; Semaglutide Reduces Alcohol Cravings; Alnylam Q4 ’24 Earnings; NYT Article Features HCPs Using GLP-1RAs; Aardvark IPOPurchase Blast
$599
Posted in: Other, Topics Feb 12 | 2025Inventiva Prioritizes Lanifibranor; TIXiMED Initiates Ph1 TIX100 Trial; Diamyd Receives Additional FinancingPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other, Topics Feb 11 | 2025Novo Warns Against Compounders; Arrowhead (FY Q1 ‘25) and Vertex CY Q4 ‘24 Earnings; Oramed Enters Agreement for Oral InsulinPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Feb 10 | 2025Lilly and OliX Partner in MASH; Hims & Hers Super Bowl Ad Controversy; Novartis Initiates Pelacarsen/Inclisiran Trial in Lp(a)Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Feb 07 | 2025Ozempic CKD Label and Website AnalysisPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 06 | 2025Orforglipron Takes Center Stage; Lilly Q4 ’24 Earnings CallPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Feb 06 | 2025AZ and Viking Q4 ’24 EarningsPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other, Topics Feb 05 | 2025Questions Remain for Cagrisema Future; Novo Q4 ‘24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Feb 04 | 2025Amgen, Pfizer, Merck, Regeneron Q4 ‘24 Earnings; Abbott Creates Diabetes FilmPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 03 | 2025Finerenone in HF Filed in EU; D&D Completes MASH Trial EnrollmentPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Jan 31 | 2025Novartis and Biocon Q4 ’24 Earnings; Metsera and Beta Bionics IPO Updates; Fractyl Business UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Other, Topics Jan 30 | 2025Roche and Sanofi Q4 ‘24 Earnings; Tectonic Interim Ph1b HFpEF DataPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jan 29 | 2025FDA Issues Warning Letter to Compounder; Lilly Discontinues HFpEF and CKD Asset; Teva Q4 ’24 EarningsPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
